IDXX

IDEXX Laboratories
D

IDXX

Arincen86/100B

IDEXX Laboratories income statement 1991–2026

4.66B USD over the last twelve months, and 4.30B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
4.66B4.30B3.90B3.66B3.37B3.22B2.71B2.41B2.21B1.97B1.78B
Revenue growth
+11.87%+10.42%+6.46%+8.72%+4.73%+18.79%+12.45%+8.75%+12.40%+10.91%+10.83%
Cost of revenue
1.74B1.64B1.52B1.47B1.36B1.33B1.14B1.04B971.70M871.68M799.99M
Gross profit
2.92B2.66B2.38B2.19B2.00B1.89B1.57B1.37B1.24B1.10B975.44M
Gross margin
62.72%61.80%61.04%59.82%59.52%58.76%58.04%56.73%56.10%55.73%54.94%
Research and development
266.87M251.21M219.79M190.95M254.82M161.01M141.25M133.19M117.86M109.18M101.12M
Selling, general and administrative
1.15B1.05B1.03B901.89M850.75M796.40M735.27M679.51M632.34M575.17M524.08M
Operating expenses
1.42B1.30B1.25B1.09B1.11B957.40M876.52M812.70M750.21M684.35M625.20M
1.51B1.36B1.13B1.10B898.77M932.03M694.52M552.85M491.34M413.03M350.24M
Operating income growth
+15.31%+20.53%+2.84%+22.07%-3.57%+34.20%+25.63%+12.52%+18.96%+17.93%+16.78%
Operating margin
32.30%31.60%28.95%29.97%26.69%28.99%25.66%22.97%22.20%20.98%19.73%
Interest income
2.76M2.42M12.70M5.63M1.07M434.00K586.00K427.00K1.15M5.25M3.66M
Interest expense
35.90M38.27M31.21M41.58M39.86M29.81M33.13M31.06M34.74M37.23M32.05M
Other non-operating income
-27.13M-35.84M-18.51M-35.95M-38.79M-29.37M-32.54M-30.63M-33.59M-31.97M-28.39M
Pretax income
1.48B1.32B1.11B1.06B859.97M902.65M661.99M522.22M457.74M381.06M321.85M
Income tax
296.78M264.73M221.96M216.13M180.88M157.81M79.85M94.43M80.70M117.79M99.79M
Effective tax rate
20.07%19.99%20.00%20.37%21.03%17.48%12.06%18.08%17.63%30.91%31.01%
1.18B1.06B887.87M845.04M679.09M744.85M581.78M427.72M377.03M263.14M222.05M
Net income growth
+15.06%+19.33%+5.07%+24.44%-8.83%+28.03%+36.02%+13.44%+43.28%+18.51%+15.60%
Net margin
25.36%24.62%22.78%23.08%20.17%23.17%21.49%17.77%17.04%13.36%12.51%
Basic shares
79.78M80.10M82.47M83.07M83.62M85.20M85.34M86.12M86.86M87.77M89.73M
Diluted shares
79.80M80.68M83.25M83.98M84.60M86.57M86.72M87.54M88.47M89.57M90.88M
Change in diluted shares
-2.13%-3.09%-0.87%-0.74%-2.28%-0.17%-0.94%-1.05%-1.22%-1.45%-2.95%
EPS (basic)
14.8313.1710.7710.178.128.746.824.974.343.002.47
EPS (diluted)
14.8313.0810.6710.068.038.606.714.894.262.942.44
EPS growth
+17.61%+22.59%+6.06%+25.28%-6.63%+28.17%+37.22%+14.79%+44.90%+20.49%+19.02%
EBITDA
1.67B1.51B1.28B1.22B1.01B1.04B793.81M643.68M575.66M501.42M431.69M
EBITDA margin
35.88%35.03%32.73%33.26%30.13%32.34%29.33%26.74%26.01%25.47%24.31%
EBIT
1.51B1.36B1.14B1.10B899.83M932.46M695.11M553.27M492.49M418.28M353.90M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about IDEXX Laboratories's income statement

Source: Financial Modeling Prep